Your browser doesn't support javascript.
loading
Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults.
Kared, Hassen; Wolf, Asia-Sophia; Alirezaylavasani, Amin; Ravussin, Anthony; Solum, Guri; Tran, Trung The; Lund-Johansen, Fridtjof; Vaage, John Torgils; Nissen-Meyer, Lise Sofie; Nygaard, Unni C; Hungnes, Olav; Robertson, Anna H; Næss, Lisbeth Meyer; Trogstad, Lill; Magnus, Per; Munthe, Ludvig A; Mjaaland, Siri.
Affiliation
  • Kared H; KG Jebsen Centre for B cell malignancy, Institute of Clinical medicine, University of Oslo, Oslo, Norway. hassen.kared@medisin.uio.no.
  • Wolf AS; Department of Immunology, Oslo University Hospital, Oslo, Norway. hassen.kared@medisin.uio.no.
  • Alirezaylavasani A; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Ravussin A; KG Jebsen Centre for B cell malignancy, Institute of Clinical medicine, University of Oslo, Oslo, Norway.
  • Solum G; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Tran TT; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Lund-Johansen F; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Vaage JT; ImmunoLingo Convergence Center, Institute of Clinical medicine, University of Oslo, Oslo, Norway.
  • Nissen-Meyer LS; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Nygaard UC; ImmunoLingo Convergence Center, Institute of Clinical medicine, University of Oslo, Oslo, Norway.
  • Hungnes O; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Robertson AH; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Næss LM; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Trogstad L; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Magnus P; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Munthe LA; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • Mjaaland S; Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Nat Commun ; 13(1): 4165, 2022 07 18.
Article in En | MEDLINE | ID: mdl-35851055
ABSTRACT
The SARS-CoV-2 Omicron variant has more than 15 mutations in the receptor binding domain of the Spike protein enabling increased transmissibility and viral escape from antibodies in vaccinated individuals. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a super-spreader event have robust recall response of humoral and pre-existing cellular immunity induced by the vaccines, and an emergent de novo T cell response to non-Spike antigens. Individuals with Omicron SARS-CoV-2 breakthrough infections have significantly increased activated SARS-CoV-2 wild type Spike-specific cytotoxic T cells, activated follicular helper (TFH) cells, functional T cell responses, boosted humoral responses, and rapid release of Spike and RBD-specific IgG+ B cell plasmablasts and memory B cells into circulation. Omicron breakthrough infection affords significantly increased de novo memory T cell responses to non-Spike viral antigens. Concerted T and B cell responses may provide durable and broad immunity.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Limits: Adult / Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Limits: Adult / Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2022 Document type: Article Affiliation country:
...